Long-term prognosis after out-of-hospital cardiac arrest and primary percutaneous coronary intervention

B Bendz1, J Eritsland, A R Nakstad

  • 1Department of Cardiology, Ullevål University Hospital, N-0407 Oslo, Norway. bendz@rikshospitalet.no

Resuscitation
|September 29, 2004
PubMed

Insights

Long-term survival is favorable for patients with ST-segment elevation myocardial infarction (STEMI) who experience out-of-hospital cardiac arrest but undergo successful cardiopulmonary resuscitation (CPR) and primary percutaneous coronary intervention (PCI). This study highlights good prognosis in selected STEMI patients post-CPR and PCI.

Area of Science:

  • Cardiology
  • Emergency Medicine
  • Clinical Research

Background:

  • Out-of-hospital cardiac arrest (OHCA) in ST-segment elevation myocardial infarction (STEMI) patients presents a significant clinical challenge.
  • Successful cardiopulmonary resuscitation (CPR) and timely reperfusion therapy are critical for improving outcomes.
  • Primary percutaneous coronary intervention (PCI) has become a standard treatment for STEMI.

Purpose of the Study:

  • To evaluate the long-term survival rates of STEMI patients who experienced OHCA and underwent successful CPR followed by primary PCI.
  • To compare the survival outcomes of this cohort with STEMI patients who did not experience cardiac arrest but received primary PCI.

Main Methods:

  • A retrospective study comparing 40 STEMI patients with OHCA and successful CPR treated with primary PCI.
  • A reference group of 325 STEMI patients without cardiac arrest, also treated with primary PCI during the same period, was used for comparison.
  • In-hospital and 2-year survival rates were analyzed for both groups.

Main Results:

  • The OHCA group (with successful CPR and primary PCI) had an in-hospital and 2-year mortality rate of 27.5%.
  • The reference STEMI group (without cardiac arrest) had in-hospital and 2-year mortality rates of 4.9% and 7.1%, respectively.
  • No significant difference in mortality was observed between the groups after hospital discharge.

Conclusions:

  • Selected STEMI patients who achieve successful CPR after OHCA and receive primary PCI demonstrate a good long-term prognosis.
  • Primary PCI is a viable and effective treatment strategy for STEMI patients, even in the context of prior cardiac arrest.
  • Further research may identify specific patient subgroups who benefit most from this aggressive treatment approach.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...